Cross-Program mRNA Process Models with Interpretable Machine Learning
The commercialization of mRNA based COVID vaccines has fulfilled the promise of mRNA science as a new generation of transformative medicines. The potential demand for variant-targeted vaccines of infectious diseases and personalized neoantigen expressing cancer vaccines require rapid process development and supply of mRNAs of newly designed sequences. Predictive in silico tools can be used to reduce the time and cost of process development and recommend optimal RNA process for new sequences.